MVP化疗联合放疗对晚期肺腺癌的疗效分析

Analysis of MVP Chemotherapy Combined with Radiotherapy for Advanced Lung Adenocarcionma

目的 探讨化疗联合放疗对晚期肺腺癌预后的影响。方法 选择 80例晚期肺腺癌 ,其中 45例采用MVP方案 (丝裂霉素、长春花碱酰胺、顺铂 )化疗 1～ 2周期后给予局部放疗 ,放疗的同时或结束后再行化疗 2～ 4周期 ;35例单纯采用MVP方案化疗 4～ 6周期。结果 放化组总缓解率为 6 6 7% ,中位生存期 19 1个月 ,其 1、2、3年生存率分别为 6 4 4%、33 3 %、15 5 %。单化组总缓解率为34 3 % ,中位生存期 9 2个月 ,其 1、2、3年生存率分别为 40 %、11 4%、0 %。放化组疗效优于单化组 (P <0 0 5 )。两组的毒副作用无统计学差异 (P >0 0 5 )。结论 MVP化疗联合放疗能改善晚期肺腺癌患者生存质量 ,延长生存期 ,提高生存率。

Objective To study the effect of MVP chemotherapy combined with radiotherapy for advanced lung adenocarcinoma.Methods 80 cases of advanced lung adenocarcinoma have been treated. 45 cases were treacted by MVP chemotherapy for 1～2 cycles at first, then followed with partial rabioterpay, at the same time or after radiontherapy, 2～4 cycles of chemotherapy were given again. The other 35 cases received 4～6 cycles of the same chemotherapy alone. Results The overall response rate in chemotherpapy plus radiotherapy group was 66.7%, median survival time was 19.1 months, and the 1-,2-,3-year survival rates were 64.6%, 33.3%,15.5%. The overall response rate in chemotherapy group was 34.3%, median survival time was 9.2 months, and the 1-,2-,3- year survival rates were 40%, 11.4%, 0%. The former is better than the later ( P <0 05) The difference of toxic effects of the two groups was not statistically significant ( P <0 05).Conclusions MVP chemotherapy combined with radiotherapy can improve survival quality, prolong survival time,improve survival rate of advanced lung adenoca rcinoma.